C a n a d a a n d t h e C a n a d i a n I n s 
METHODS

Subjects and Ethics Statement
This study was approved by the Institutional Review Board of the University of Utah. All participants gave written consent, which included DNA sampling for molecular studies and access to medical records.
An initial set of pancreatic cancer cases (n=66) were selected on the minimal requirements of personal history of cancer and having at least two grandparents in the genealogy data represented in the Utah Population Database (UPDB). These patients were screened with a 34-gene custom research panel. Individual family members were then linked to statewide cancer, demographic, and medical information. 
Sequence variant evaluation
Truncating variants not present in the final exon of a gene were considered pathogenic.
The following filters were used to exclude variants from further analysis: minor allele frequency ≥ 0.1% in one or more populations from the Exome Aggregation Consortium (ExAC) database; [30] synonymous/intronic variants with no predicted effect on splicing via
MaxEntScan; [31] variants reported as probable-non-pathogenic/non-pathogenic by more than one source with no conflicting reports in ClinVar (www.ncbi.nlm.nih.gov/clinvar).
Variants of uncertain significance (VUS) were included if their estimated prior probabilities of pathogenicity were >0.8 based on calibrated in silico predictions from publicly available databases for the mismatch repair (MMR) genes (hci-lovd.hci.utah.edu), or BRCA1/2 (http://priors.hci.utah.edu/PRIORS/). VUS of this type were weighted according to their sequence analysis-based prior probability of pathogenicity (Prior_P) score. The remaining rare VUS were included if at least three of the four missense analysis programs Align-GVGD, MAPP, Polyphen-2, and CADD predicted a severe score. [32] [33] [34] [35] [36] This filter corresponds with an OR=3.27 when comparing early-onset breast cancer cases with matched controls. [35] Based on the likelihood ratios identified for BRCA1/2, [37] this grouping was assigned a weight of 0.81; from here forward, we refer to these as high probability of pathogenicity VUS (HiP-VUS).
Canonical splice acceptor/donor variants predicted to impact splicing were given the weight of and SIR calculation, the genes were split into subgroups of high-and moderate-risk cancer susceptibility genes. High-and moderate-risk were defined as genes with a cumulative risk at age 80 >32% or between 19-32%, respectively, for the cancer with which they are most closely associated.
[2] The R package ggplot2 was used to plot the meta-analyses and SIRs. [43] 
RESULTS
Pancreatic cancer, unselected for family history
In an initial set of 66 pancreatic cancer cases unselected for family history of cancer, 4 pathogenic variants were identified in BRCA2, MSH6, PALB2, and STK11. After filtering VUS to those with elevated probabilities of pathogenicity, 2 HiP-VUS in ATM remained (Table 1) .
After weighting, 8.5% of these pancreatic cancer cases carried a variant with potential medical management impact for relatives.
To replicate this observation, 156 independent pancreatic cancer cases underwent hereditary cancer predisposition multigene panel testing (n=96 tested with the 59-gene research panel of which one sample failed, and n=61 tested with the 14-gene clinical panel after 12 declined testing). Ten pathogenic variants and seven HiP-VUS were identified (Table 1) . These were all identified in genes included in the 34-gene panel. In addition to in silico predictions, CHEK2 p.(T476M) was found to be damaging in a functional assay for CHEK2 variants and was weighted more strongly towards being pathogenic. [44] After weighting carriers, we found 9.1% of the replication series of pancreatic cancer cases, unselected for family history, carried a variant with potential medical impact.
Post-variant evaluation of genetic testing eligibility
In order to determine if the pancreatic cancer cases would have qualified for genetic testing, we compared the pancreatic cancer cases that carried pathogenic variants or HiP-VUS with their self-reported family history to published NCCN guidelines. [45] For our initial 66 pancreatic cancer cases, we also were able to access their family history of cancer from UPDB (Supplemental Figure 1) . Outside of the STK11 carrier's family (who had a clinical diagnosis of Peutz-Jegher syndrome), in which the mother and sister had previously been diagnosed, none of the biological relatives had undergone cascade genetic testing.
Meta-analysis of carrier proportions across studies
The two HCH sets of pancreatic cancer cases were combined with a published study of unselected pancreatic cancer cases from the Mayo Clinic (n=96), [39] plus the pancreatic cancer cases from TCGA (n=154), in a meta-analysis (Figure 2 ; Supplemental Table 3 ; Supplemental weighted HiP-VUS with elevated probability of pathogenicity that could enable the at-risk relatives to qualify for preventive HBOC or CRC measures.
Further, the gene burdens observed in the Utah, Mayo, and TCGA were compared to the non-TCGA ExAC (n=49,451, excluding the Finnish and other subpopulations) as a population sample to determine SIR for subgroups of genes ( Figure 3 , Supplemental Table 5 ). As a group, the high-risk susceptibility genes had a SIR = 3.1 (p=2.1x10 -05 ). The moderate-risk HRR genes had a slightly lower SIR = 2.4 (p=9.2x10 -05 ).
Discussion
Through systematic panel testing of pancreatic cancer cases unselected for family history, we estimate that 2.7% (95% CI followed by germline testing for indicated individuals, is recommended for newly diagnosed CRC cases. [47, 51] This strategy may soon be overtaken by germline DNA panel testing for LS due to 1) rapid decline of panel testing cost, 2) superiority of specificity and sensitivity, and 3)
evidence that pre-screening delays testing, which results in a subsequent ~50% loss in follow-up by patients. [52] [53] [54] [55] [56] [57] [58] [59] Indeed, a health economics analysis recently published by Erten et al. [59] concluded that universal testing of CRC patients for LS based on sequencing alone will become more cost-effective than the two-step test when the cost of MMR gene sequencing drops to or below $609 USD, echoing a similar finding by Gould-Suarez et al. [59, 60] Since the proportion of carriers are similar for pancreatic and metastatic prostate cancer, both of these areas will need to be re-evaluated for guideline updates. For these patients, universal panel testing offers critical time and convenience advantages over cascade testing strategies, resulting in a decreased loss to follow-up or mortality and correspondingly increased benefit to at-risk relatives.
Results In the second set of unselected pancreatic cancer cases, one case failed testing with the custom 59-gene panel and 12 cases declined testing with the Invitae hciPancreasCA panel. MAF = minor allele frequency; HiP-VUS = high probability of pathogenicity variant of uncertain significance;
MMR -mismatch repair; Prior_P = sequence analysis-based prior probability of pathogenicity. Results based on a meta-analysis of the unselected pancreatic cancer cases from the Huntsman Cancer Hospital (HCH), the Mayo Clinic, and the pancreatic cancer cases from The Cancer Genome Atlas (TCGA). Carrier frequency point estimates and 95% confidence intervals for groups of genes are presented on a log-scale. A list of genes contained within each analysis group is provided in Supplemental Table 1 . The breakdown of results by study is described in Supplemental Table 3 Table 5 . A list of genes contained within each analysis group is provided in Supplemental Table 1 . Error bars represent 95% confidence intervals. HBOC =
